1. FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma. FDA. February 13, 2024. Accessed February 13, 2024.网页链接 2. Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI
来源: [1]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma [2]https://www.onclive.com/view/fda-approves-frontline-nalirif...
Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)fluorouracilalbuminsconflict of interestdiarrhearegimengemcitabinebrachial plexus neuritisca-19-9 antigen...
胰腺癌是一种发病率持续攀升的侵袭性全身性疾病,预计到2030年将成为癌症相关死亡的第二大常见原因。胰腺癌的预后普遍较差,相关诊疗指南中标准诊疗路径和标准治疗方案的更新一直为广大临床医生所关注。近日,NCCN发布了2023.V2版胰腺癌诊疗指南¹,...
liposomal irinotecan 50 mg/m2+ 5-FU 2400 mg/m2+ LV 400 mg/m2+ oxaliplatin 60 mg/m2(NALIRIFOX) 相比经典的FOLFIRINOX和改良版FOLFIRINOX,该方案的焦点在于伊立替康,虽然剂型不同无从比较,不过从临床研究的目的来看,减毒增效...
[1] Abstract LBA661:NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients wi...
1. FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma. FDA. February 13, 2024. Accessed February 14, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma...
Thereby, novel drug formulations like nanoliposomal-irinotecan (nal-IRI) in combination with 5- fluorouracil (5-FU)/ leucovorin may have the potential to improve therapeutic outcomes in this disease. Methods: NIFE is an interventional, prospective, randomized, controlled, open label, two-sided ...
Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes. With the high association of diarrhea with NALIRIFOX (liposomal irinotecan [Onivyde], 5-fluorouracil [5-FU]/leucovori...
Question Does fluorouracil, leucovorin, liposomal irinotecan and oxaliplatin (NALIFIROX) confer a survival benefit as first-line treatment for patients with metastatic pancreatic cancer compared with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine with nab-paclitaxel (GEM-NAB...